These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16215315)

  • 21. lncRNA Up-Regulated in Nonmuscle Invasive Bladder Cancer Facilitates Tumor Growth and Acts as a Negative Prognostic Factor of Recurrence.
    Zhang S; Zhong G; He W; Yu H; Huang J; Lin T
    J Urol; 2016 Oct; 196(4):1270-8. PubMed ID: 27267320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
    Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
    J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer.
    Atlasi Y; Mowla SJ; Ziaee SA; Bahrami AR
    Int J Cancer; 2007 Apr; 120(7):1598-602. PubMed ID: 17205510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
    Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
    Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent expression of zinc-finger protein ZNF165 in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML
    Immunobiology; 2015 Jan; 220(1):68-73. PubMed ID: 25214475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 27.  Effect of siRNA targeting EZH2 on cell viability and apoptosis of bladder cancer T24 cells.
    Wang HF; Yang H; Hu LB; Lei YH; Qin Y; Li J; Bi CW; Wang JS; Huo Q
    Genet Mol Res; 2014 Nov; 13(4):9939-50. PubMed ID: 25501205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
    Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
    Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
    Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
    Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
    Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
    Choi JH; Song YS; Yoon JS; Song KW; Lee YY
    APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
    Hwang CF; Huang HY; Chen CH; Chien CY; Hsu YC; Li CF; Fang FM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):597-604. PubMed ID: 21300475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells.
    Yang YM; Chang JW
    Cancer Invest; 2008 Aug; 26(7):725-33. PubMed ID: 18608209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
    Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
    Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder.
    Yin B; Liu G; Wang XS; Zhang H; Song YS; Wu B
    Urol Oncol; 2012; 30(6):886-92. PubMed ID: 21396841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metallothionein isoform 3 as a potential biomarker for human bladder cancer.
    Sens MA; Somji S; Lamm DL; Garrett SH; Slovinsky F; Todd JH; Sens DA
    Environ Health Perspect; 2000 May; 108(5):413-8. PubMed ID: 10811567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.
    Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F
    Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
    Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
    Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.